BioNxt: Accelerating Drug Delivery Innovations in Europe

BioNxt Solutions Inc. (CSE:BNXT)(OTC:BNXTF) is poised to accelerate its drug delivery innovations with a strategic relocation to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany. This move, set to commence on March 1, 2025, will provide BioNxt with access to state-of-the-art technologies, an expanded research environment, and opportunities for scientific collaboration within Europe's biotech hub.



The Gen-Plus Laboratory offers BioNxt a 1,000-square-meter research facility equipped for high-potency active pharmaceutical ingredients and GMP-compliant processes. This cutting-edge infrastructure includes specialized equipment for solid and semi-solid dosage forms and drug printing capabilities, empowering BioNxt to:

* Accelerate preclinical research timelines
* Enhance formulation accuracy
* Streamline the development of next-generation therapeutics

By leveraging the advanced capabilities at the Gen-Plus Laboratory, BioNxt's innovative projects, such as the development of advanced drug delivery systems like sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.

The Munich location also offers strategic opportunities for scientific collaboration with leading research institutions, biotech firms, and academic experts. This collaboration can lead to faster innovation, access to new ideas and expertise, and potential partnerships for co-development and commercialization.

Hugh Rogers, CEO of BioNxt Solutions Inc., emphasizes the strategic importance of this relocation, stating, "BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt... unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide." This relocation is expected to have a significant impact on BioNxt's current and future projects, accelerating its progress in drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.

In conclusion, BioNxt's strategic partnership with Gen-Plus and relocation to the Munich facility will accelerate its drug delivery innovations, enhance its intellectual property portfolio, and strengthen its position in the European biotech market. By harnessing the advanced capabilities and collaborative opportunities offered by the Gen-Plus Laboratory, BioNxt is well-positioned to drive innovation and deliver transformative therapies for patients worldwide.